Institutional members access full text with Ovid®

Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration

Hudelson, Sarah Ea; McConnell, Michelle Sb; Bagenda, Danstanc,d; Piwowar-Manning, Estellea; Parsons, Teresa Le; Nolan, Monica Lf; Bakaki, Paul Mg; Thigpen, Michael Cb; Mubiru, Michaeld; Fowler, Mary Glenna; Eshleman, Susan Ha

doi: 10.1097/QAD.0b013e3283346e60
Clinical Science: Concise Communication

Objective: Single-dose nevirapine (NVP) (sdNVP) can reduce the risk of HIV vertical transmission. We assessed risk factors for NVP resistance in plasma and breast milk from sdNVP-exposed Ugandan women.

Methods: Samples were analyzed using the Roche AMPLICOR HIV-1 Monitor Test Kit, version 1.5, and the ViroSeq HIV-1 Genotyping System. NVP concentrations were determined by liquid chromatography with tandem mass spectroscopy.

Results: HIV genotypes (plasma and breast milk) were obtained for 30 women 4 weeks after sdNVP (HIV subtypes: 15A, 1C, 12D, two recombinant). NVP resistance was detected in 12 (40%) of 30 breast milk samples. There was a nonsignificant trend between detection of NVP resistance in breast milk and plasma (P = 0.06). There was no association of HIV resistance in breast milk with median maternal pre-NVP viral load or CD4 cell count, median breast milk viral load at 4 weeks, breast milk sodium more than 10 mmol/l, HIV subtype, or concentration of NVP in breast milk or plasma.

Conclusion: NVP resistance was frequently detected in breast milk 4 weeks after sdNVP exposure. In this study, we were unable to identify specific factors associated with breast milk NVP resistance.

aDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

bEpidemiology Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

cMakerere University, School of Public Health, Uganda

dMakerere University – Johns Hopkins University Research Collaboration, Kampala, Uganda

eDepartment of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

fDepartment of Strategic Information, mothers2mothers, Cape Town, South Africa

gDepartment of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA.

Received 29 September, 2009

Revised 19 October, 2009

Accepted 20 October, 2009

Correspondence to Professor Susan H. Eshleman, MD, PhD, Department of Pathology, Johns Hopkins University, School of Medicine, Ross Building 646, 720 Rutland Avenue, Baltimore, MD 21205, USA. Tel: +1 410 614 4734; fax: +1 410 502 9244; e-mail: seshlem@jhmi.edu

© 2010 Lippincott Williams & Wilkins, Inc.